Skip to main content
SpringerLink
Log in

Implementation of Evidence-Based Care in the Sickle Cell and Hemophilia Patient Population

  • Chapter
  • First Online:
Book cover Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation

  • 702 Accesses

Abstract

Practice guidelines have been developed for pediatric patients with hematologic disorders, and similar to guidelines for other diseases, adherence is variable. Quality improvement initiatives can move implementation of the guidelines from variable to frequent. For children with sickle cell disease (SCD), quality improvement interventions have significantly improved outcomes related to the effective and timely management of acute vaso-occlusive crises (VOC), reducing the frequency of VOC necessitating hospitalization by administration of hydroxyurea, prevention of stroke, and reducing infections such as influenza. Although there are guidelines for the care and treatment of children with hemophilia, quality improvement initiatives are in the early stages.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–6.

    Article  CAS  PubMed  Google Scholar 

  2. Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005;130(3):437–44.

    Article  PubMed  Google Scholar 

  3. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–31.

    Article  CAS  PubMed  Google Scholar 

  4. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–7.

    Article  PubMed  Google Scholar 

  5. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314(25):1593–9.

    Article  CAS  PubMed  Google Scholar 

  6. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81(6):749–55.

    CAS  PubMed  Google Scholar 

  7. Tsevat J, Wong JB, Pauker SG, Steinberg MH. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr. 1991;118(4 Pt 1):546–54.

    Article  CAS  PubMed  Google Scholar 

  8. Shafer FE, Lorey F, Cunningham GC, Klumpp C, Vichinsky E, Lubin B. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hematol Oncol. 1996;18(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  9. Chesney PJ, Wilimas JA, Presbury G, et al. Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease. J Pediatr. 1995;127(4):526–32.

    Article  CAS  PubMed  Google Scholar 

  10. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics. 2000;106(5):965–72.

    Article  PubMed  Google Scholar 

  11. Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297(17):897–900.

    Article  CAS  PubMed  Google Scholar 

  12. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44.

    Article  CAS  PubMed  Google Scholar 

  13. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer. 2009;53(4):642–6.

    Article  PubMed  Google Scholar 

  15. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94–101.

    Article  PubMed  Google Scholar 

  16. Yusuf HR, Atrash HK, Grosse SD, Parker CS, Grant AM. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007. Am J Prev Med. 2010;38(4 Suppl):S536–41.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288–94.

    Article  CAS  PubMed  Google Scholar 

  18. Wang CJ, Kavanagh PL, Little AA, Holliman JB, Sprinz PG. Quality-of-care indicators for children with sickle cell disease. Pediatrics. 2011;128(3):484–93.

    PubMed  Google Scholar 

  19. Crosby LE, Simmons K, Kaiser P, et al. Using quality improvement methods to implement an electronic medical record (EMR) supported individualized home pain management plan for children with sickle cell disease. J Clin Outcomes Manag. 2014;21(5):210–7.

    PubMed  PubMed Central  Google Scholar 

  20. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–48.

    Article  PubMed  CAS  Google Scholar 

  21. Jacob E. Pain management in sickle cell disease. Pain Manag Nurs. 2001;2(4):121–31.

    Article  CAS  PubMed  Google Scholar 

  22. Benjamin L. Pain management in sickle cell disease: palliative care begins at birth? Hematol Am Soc Hematol Educ Program. 2008:466–74

    Google Scholar 

  23. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19(5):785–802. v

    Article  PubMed  Google Scholar 

  24. Todd KH, Green C, Bonham Jr VL, Haywood Jr C, Ivy E. Sickle cell disease related pain: crisis and conflict. J Pain. 2006;7(7):453–8.

    Article  PubMed  Google Scholar 

  25. Raphael JL, Kamdar A, Wang T, Liu H, Mahoney DH, Mueller BU. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatr Blood Cancer. 2008;51(3):398–401.

    Article  PubMed  Google Scholar 

  26. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95(4):1130–6.

    CAS  PubMed  Google Scholar 

  27. Adewoye AH, Nolan V, McMahon L, Ma Q, Steinberg MH. Effectiveness of a dedicated day hospital for management of acute sickle cell pain. Haematologica. 2007;92(6):854–5.

    Article  PubMed  Google Scholar 

  28. Whiteman LN, Lanzkron S, Stewart RW, Haywood C, Strouse JJ, Feldman L. Quality improvement process in a sickle cell infusion center. Am J Med. 2015;128(5):541–4.

    Article  PubMed  Google Scholar 

  29. Tanabe P, Thornton VL, Martinovich Z, Todd KH, Wun T, Lyons JS. The emergency department sickle cell assessment of needs and strengths (ED-SCANS): reliability and validity. Adv Emerg Nurs J. 2013;35(2):143–53.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Tanabe P, Dias N, Gorman L. Care of children with sickle cell disease in the emergency department: parent and provider perspectives inform quality improvement efforts. J Pediatr Oncol Nurs. 2013;30(4):205–17.

    Article  PubMed  Google Scholar 

  31. Gilboy N, Tanabe P, Travers DA. The emergency severity index version 4: changes to ESI level 1 and pediatric fever criteria. J Emerg Nurs. 2005;31(4):357–62.

    Article  PubMed  Google Scholar 

  32. Givens M, Rutherford C, Joshi G, Delaney K. Impact of an emergency department pain management protocol on the pattern of visits by patients with sickle cell disease. J Emerg Med. 2007;32(3):239–43.

    Article  PubMed  Google Scholar 

  33. Treadwell MJ, Bell M, Leibovich SA, et al. A quality improvement initiative to improve emergency Department Care for Pediatric Patients with sickle cell disease. J Clin Outcomes Manag. 2014;21(2):62–70.

    PubMed  PubMed Central  Google Scholar 

  34. Kavanagh PL, Sprinz PG, Wolfgang TL, et al. Improving the Management of Vaso-Occlusive Episodes in the pediatric emergency department. Pediatrics. 2015;136(4):e1016–25.

    Article  PubMed  Google Scholar 

  35. Morrissey LK, Shea JO, Kalish LA, Weiner DL, Branowicki P, Heeney MM. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer. 2009;52(3):369–72.

    Article  PubMed  Google Scholar 

  36. Olney RS. Preventing morbidity and mortality from sickle cell disease. A public health perspective. Am J Prev Med. 1999;16(2):116–21.

    Article  CAS  PubMed  Google Scholar 

  37. Udezue E, Herrera E. Pain management in adult acute sickle cell pain crisis: a viewpoint. West Afr J Med. 2007;26(3):179–82.

    CAS  PubMed  Google Scholar 

  38. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Comparison in patients in the emergency department. Arch Intern Med. 1991;151(7):1373–8.

    Article  CAS  PubMed  Google Scholar 

  39. McPherson E, Perlin E, Finke H, Castro O, Pittman J. Patient-controlled analgesia in patients with sickle cell vaso-occlusive crisis. Am J Med Sci. 1990;299(1):10–2.

    Article  CAS  PubMed  Google Scholar 

  40. van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82(11):955–60.

    Article  PubMed  CAS  Google Scholar 

  41. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. Am J Dis Child. 1986;140(12):1255–59.

    Google Scholar 

  42. Holbrook CT. Patient-controlled analgesia pain management for children with sickle cell disease. J Assoc Acad Minor Phys. 1990;1(3):93–6.

    CAS  PubMed  Google Scholar 

  43. Alexander M, Richtsmeier AJ, Broome ME, Barkin R. A multidisciplinary approach to pediatric pain: an empirical analysis. Child Health Care. 1993;22(2):81–91.

    Article  CAS  PubMed  Google Scholar 

  44. Dalton JA, Blau W, Lindley C, Carlson J, Youngblood R, Greer SM. Changing acute pain management to improve patient outcomes: an educational approach. J Pain Symptom Manag. 1999;17(4):277–87.

    Article  CAS  Google Scholar 

  45. Miaskowski C, Nichols R, Brody R, Synold T. Assessment of patient satisfaction utilizing the American pain Society’s quality assurance standards on acute and cancer-related pain. J Pain Symptom Manag. 1994;9(1):5–11.

    Article  CAS  Google Scholar 

  46. Ward SE, Gordon D. Application of the American pain society quality assurance standards. Pain. 1994;56(3):299–306.

    Article  CAS  PubMed  Google Scholar 

  47. Bookbinder M, Coyle N, Kiss M, et al. Implementing national standards for cancer pain management: program model and evaluation. J Pain Symptom Manag. 1996;12(6):334–47. discussion 331-333

    Article  CAS  Google Scholar 

  48. Francke AL, Luiken JB, de Schepper AM, Abu-Saad HH, Grypdonck M. Effects of a continuing education program on nurses' pain assessment practices. J Pain Symptom Manag. 1997;13(2):90–7.

    Article  CAS  Google Scholar 

  49. Allen Liles E, Kirsch J, Gilchrist M, Adem M. Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care. Hosp Pract (1995). 2014;42(2):70–76.

    Google Scholar 

  50. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–9.

    Article  CAS  PubMed  Google Scholar 

  51. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–58.

    Article  CAS  PubMed  Google Scholar 

  53. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–70.

    Article  CAS  PubMed  Google Scholar 

  54. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–22.

    Article  CAS  PubMed  Google Scholar 

  56. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore) 1996;75(6):300–326.

    Google Scholar 

  57. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–63.

    Article  CAS  PubMed  Google Scholar 

  60. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161(6):852–60.

    Article  CAS  PubMed  Google Scholar 

  61. Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79(2):107–13.

    Article  CAS  PubMed  Google Scholar 

  62. Anders DG, Tang F, Ledneva T, et al. Hydroxyurea use in young children with sickle cell anemia in New York state. Am J Prev Med. 2016;51(1 Suppl 1):S31–8.

    Article  PubMed  Google Scholar 

  63. Stettler N, McKiernan CM, Melin CQ, Adejoro OO, Walczak NB. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015;313(16):1671–2.

    Article  PubMed  Google Scholar 

  64. Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13(1):19–24.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatr Blood Cancer. 2016;63(12):2146–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Haywood C, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86(1):85–7.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–9.

    Article  CAS  PubMed  Google Scholar 

  68. Inoue S, Kodjebacheva G, Scherrer T, et al. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study. Int J Hematol. 2016;104(2):200–7.

    Article  CAS  PubMed  Google Scholar 

  69. Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL. Impact of a clinical pharmacy service on the management of patients in a sickle cell disease outpatient center. Pharmacotherapy. 2016;36(11):1166–72.

    Article  CAS  PubMed  Google Scholar 

  70. Pai AL, McGrady ME. Assessing medication adherence as a standard of Care in Pediatric Oncology. Pediatr Blood Cancer. 2015;62(Suppl 5):S818–28.

    Article  PubMed  Google Scholar 

  71. McGrady ME, Ryan JL, Gutiérrez-Colina AM, Fredericks EM, Towner EK, Pai AL. The impact of effective paediatric adherence promotion interventions: systematic review and meta-analysis. Child Care Health Dev. 2015;41(6):789–802.

    Article  CAS  PubMed  Google Scholar 

  72. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–94.

    CAS  PubMed  Google Scholar 

  73. Lee MT, Piomelli S, Granger S, et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.

    Article  CAS  PubMed  Google Scholar 

  75. Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood. 2004;104(2):336–9.

    Article  CAS  PubMed  Google Scholar 

  76. Armstrong-Wells J, Grimes B, Sidney S, et al. Utilization of TCD screening for primary stroke prevention in children with sickle cell disease. Neurology. 2009;72(15):1316–21.

    Article  CAS  PubMed  Google Scholar 

  77. Enninful-Eghan H, Moore RH, Ichord R, Smith-Whitley K, Kwiatkowski JL. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr. 2010;157(3):479–84.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lehman LL, Fullerton HJ. Changing ethnic disparity in ischemic stroke mortality in US children after the STOP trial. JAMA Pediatr. 2013;167(8):754–8.

    Article  PubMed  Google Scholar 

  79. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer. 2013;60(5):823–7.

    Article  PubMed  Google Scholar 

  80. Genetics SoHOCo, Pediatrics AAo. Health supervision for children with sickle cell disease. Pediatrics. 2002;109(3):526–35.

    Article  Google Scholar 

  81. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003;327(7424):1151–5.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Cherry MG, Greenhalgh J, Osipenko L, et al. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Health Technol Assess. 2012;16(43):1–129.

    Article  CAS  Google Scholar 

  83. Raphael JL, Shetty PB, Liu H, Mahoney DH, Mueller BU. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer. 2008;51(5):647–51.

    Article  PubMed  Google Scholar 

  84. Fullerton HJ, Gardner M, Adams RJ, Lo LC, Johnston SC. Obstacles to primary stroke prevention in children with sickle cell disease. Neurology. 2006;67(6):1098–9.

    Article  CAS  PubMed  Google Scholar 

  85. Bollinger LM, Nire KG, Rhodes MM, Chisolm DJ, O'Brien SH. Caregivers' perspectives on barriers to transcranial Doppler screening in children with sickle-cell disease. Pediatr Blood Cancer. 2011;56(1):99–102.

    Article  PubMed  Google Scholar 

  86. McCarville MB, Goodin GS, Fortner G, et al. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatr Blood Cancer. 2008;50(4):818–21.

    Article  PubMed  Google Scholar 

  87. El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology. 2010;52(2):403–7.

    Article  PubMed  Google Scholar 

  88. Crosby LE, Joffe NE, Davis B, et al. Implementation of a process for initial transcranial Doppler ultrasonography in children with sickle cell anemia. Am J Prev Med. 2016;51(1 Suppl 1):S10–6.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Hussain S, Nichols F, Bowman L, Xu H, Neunert C. Implementation of transcranial Doppler ultrasonography screening and primary stroke prevention in urban and rural sickle cell disease populations. Pediatr Blood Cancer. 2015;62(2):219–23.

    Article  PubMed  Google Scholar 

  90. Muntz DS, Bundy DG, Strouse JJ. Personalized reminders increase screening for stroke risk in children with sickle cell anemia. South Med J. 2016;109(9):506–10.

    Article  PubMed  Google Scholar 

  91. Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics. 2010;125(2):234–43.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428–33.

    Article  CAS  PubMed  Google Scholar 

  93. Sobota AE, Kavanagh PL, Adams WG, McClure E, Farrell D, Sprinz PG. Improvement in influenza vaccination rates in a pediatric sickle cell disease clinic. Pediatr Blood Cancer. 2015;62(4):654–7.

    Article  PubMed  Google Scholar 

  94. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–97.

    Article  PubMed  Google Scholar 

  95. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–9.

    Article  CAS  PubMed  Google Scholar 

  96. Rosendaal FR, Briët E. The increasing prevalence of haemophilia. Thromb Haemost. 1990;63(1):145.

    CAS  PubMed  Google Scholar 

  97. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.

    Article  CAS  PubMed  Google Scholar 

  98. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012;18(2):276–83.

    Article  CAS  PubMed  Google Scholar 

  99. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia. 2012;18(2):268–75.

    Article  CAS  PubMed  Google Scholar 

  100. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361–74.

    Article  CAS  PubMed  Google Scholar 

  101. Dandoy CE, Hariharan S, Weiss B, et al. Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborative. BMJ Qual Saf. 2016;25(2):100–9.

    Article  PubMed  Google Scholar 

  102. Fletcher M, Hodgkiss H, Zhang S, et al. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer. 2013;60(8):1299–306.

    Article  CAS  PubMed  Google Scholar 

  103. Volpe D, Harrison S, Damian F, et al. Improving timeliness of antibiotic delivery for patients with fever and suspected neutropenia in a pediatric emergency department. Pediatrics. 2012;130(1):e201–10.

    Article  PubMed  Google Scholar 

  104. Tagliaferri A, Di Perna C, Biasoli C, et al. A web site to improve Management of Patients with inherited bleeding disorders in the emergency department: results at 2 years. Semin Thromb Hemost. 2016;42(5):589–98.

    Article  PubMed  Google Scholar 

  105. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ. 2012;344:e2707.

    Article  PubMed  Google Scholar 

  106. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–44.

    Article  CAS  PubMed  Google Scholar 

  107. Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia. 2013;19(3):355–61.

    Article  CAS  PubMed  Google Scholar 

  108. Thornburg C. Prophylactic factor infusions for patients with hemophilia: challenges with treatment adherence. J Coagul Disord. 2010;2:9–14.

    Google Scholar 

  109. Kyngäs H. Compliance of adolescents with chronic disease. J Clin Nurs. 2000;9(4):549–56.

    Article  PubMed  Google Scholar 

  110. Witkop ML, McLaughlin JM, Anderson TL, Munn JE, Lambing A, Tortella B. Predictors of non-adherence to prescribed prophylactic clotting-factor treatment regimens among adolescent and young adults with a bleeding disorder. Haemophilia. 2016;22(4):e245–50.

    Article  CAS  PubMed  Google Scholar 

  111. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia a. Haemophilia. 1997;3(2):96–101.

    Article  CAS  PubMed  Google Scholar 

  112. Ar MC, Vaide I, Berntorp E, Björkman S. Methods for individualising factor VIII dosing in prophylaxis. Eur J Haematol Suppl. 2014;76:16–20.

    Article  CAS  PubMed  Google Scholar 

  113. Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood. 2006;108(12):3668–73.

    Article  CAS  PubMed  Google Scholar 

  114. Quon D, Reding M, Guelcher C, et al. Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. Am J Hematol. 2015;90(Suppl 2):S17–22.

    Article  PubMed  Google Scholar 

  115. Bahr NC, Song J. The effect of structural violence on patients with sickle cell disease. J Health Care Poor Underserved. 2015;26(3):648–61.

    Article  PubMed  Google Scholar 

  116. Porter JS, Matthews CS, Carroll YM, Anderson SM, Smeltzer MP, Hankins JS. Genetic education and sickle cell disease: feasibility and efficacy of a program tailored to adolescents. J Pediatr Hematol Oncol. 2014;36(7):572–7.

    Article  PubMed  Google Scholar 

  117. Frost JR, Cherry RK, Oyeku SO, et al. Improving sickle cell transitions of care through health information technology. Am J Prev Med. 2016;51(1 Suppl 1):S17–23.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, USA

    Karen A. Kalinyak

  2. Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, USA

    Christopher E. Dandoy

  3. Department of Pediatric Hematology, Children’s Hospital Colorado, 13123 East 16th Ave, Aurora, CO, USA

    Rachelle Nuss

Authors
  1. Karen A. Kalinyak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher E. Dandoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rachelle Nuss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen A. Kalinyak .

Editor information

Editors and Affiliations

  1. Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

    Christopher E. Dandoy

  2. Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, Colorado, USA

    Joanne M. Hilden

  3. Boston Children’s Cancer and Blood Disorders Center, Dana-Farber, Boston, Massachusetts, USA

    Amy L. Billett

  4. Johns Hopkins All Children’s Hospital, St. Petersburg, Florida, USA

    Brigitta U. Mueller

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kalinyak, K.A., Dandoy, C.E., Nuss, R. (2017). Implementation of Evidence-Based Care in the Sickle Cell and Hemophilia Patient Population. In: Dandoy, C., Hilden, J., Billett, A., Mueller, B. (eds) Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-53790-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53790-0_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53788-7

  • Online ISBN: 978-3-319-53790-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation